312 related articles for article (PubMed ID: 37638827)
1. The Role of Traditional Chinese Medicine in Cancer Immunotherapy: Current Status and Future Directions.
Xie J; Huang H; Li X; Ouyang L; Wang L; Liu D; Wei X; Tan P; Tu P; Hu Z
Am J Chin Med; 2023; 51(7):1627-1651. PubMed ID: 37638827
[TBL] [Abstract][Full Text] [Related]
2. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic strategies for gastric cancer targeting immune cells: Future directions.
Zhao Y; Bai Y; Shen M; Li Y
Front Immunol; 2022; 13():992762. PubMed ID: 36225938
[TBL] [Abstract][Full Text] [Related]
4. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
5. Research Status and Molecular Mechanism of the Traditional Chinese Medicine and Antitumor Therapy Combined Strategy Based on Tumor Microenvironment.
Zhang Y; Lou Y; Wang J; Yu C; Shen W
Front Immunol; 2020; 11():609705. PubMed ID: 33552068
[TBL] [Abstract][Full Text] [Related]
6. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.
Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM
JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399
[TBL] [Abstract][Full Text] [Related]
7. Interplay between inflammasomes and PD-1/PD-L1 and their implications in cancer immunotherapy.
Jiao Z; Zhang J
Carcinogenesis; 2023 Dec; 44(12):795-808. PubMed ID: 37796835
[TBL] [Abstract][Full Text] [Related]
8. Traditional Chinese medicine inhibits PD-1/PD-L1 axis to sensitize cancer immunotherapy: a literature review.
Zheng H; Wang G; Liu M; Cheng H
Front Oncol; 2023; 13():1168226. PubMed ID: 37397393
[TBL] [Abstract][Full Text] [Related]
9. PD1/PD-L1 immune checkpoint as a potential target for preventing brain tumor progression.
Filippone A; Lanza M; Mannino D; Raciti G; Colarossi C; Sciacca D; Cuzzocrea S; Paterniti I
Cancer Immunol Immunother; 2022 Sep; 71(9):2067-2075. PubMed ID: 35092481
[TBL] [Abstract][Full Text] [Related]
10. Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy.
Liu K; Sun Q; Liu Q; Li H; Zhang W; Sun C
Biomed Pharmacother; 2022 Oct; 154():113618. PubMed ID: 36055113
[TBL] [Abstract][Full Text] [Related]
11. Phytochemicals in regulating PD-1/PD-L1 and immune checkpoint blockade therapy.
Zhang Q; Yang C; Gao X; Dong J; Zhong C
Phytother Res; 2024 Feb; 38(2):776-796. PubMed ID: 38050789
[TBL] [Abstract][Full Text] [Related]
12. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
13. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
14. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
15. Extracellular vesicle-based checkpoint regulation and immune state in cancer.
Mortezaee K; Majidpoor J
Med Oncol; 2022 Sep; 39(12):225. PubMed ID: 36175741
[TBL] [Abstract][Full Text] [Related]
16. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
[TBL] [Abstract][Full Text] [Related]
17. Anticancer natural products targeting immune checkpoint protein network.
Chun KS; Kim DH; Raut PK; Surh YJ
Semin Cancer Biol; 2022 Nov; 86(Pt 3):1008-1032. PubMed ID: 34838956
[TBL] [Abstract][Full Text] [Related]
18. The traditional chinese medicine monomer Ailanthone improves the therapeutic efficacy of anti-PD-L1 in melanoma cells by targeting c-Jun.
Yu P; Wei H; Li K; Zhu S; Li J; Chen C; Zhang D; Li Y; Zhu L; Yi X; Liu N; Liu P; Zhao S; Chen X; Peng C
J Exp Clin Cancer Res; 2022 Dec; 41(1):346. PubMed ID: 36522774
[TBL] [Abstract][Full Text] [Related]
19. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
20. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
[Next] [New Search]